Elsevier

Clinical Lung Cancer

Volume 9, Supplement 3, March 2008, Pages S109-S115
Clinical Lung Cancer

Integrating Epidermal Growth Factor Receptor–Targeted Therapies into Platinum-Based Chemotherapy Regimens for Newly Diagnosed Non–Small-Cell Lung Cancer

https://doi.org/10.3816/CLC.2008.s.016Get rights and content

Abstract

Cytotoxic chemotherapy treatment for patients with advanced non–small-cell lung cancer (NSCLC) has reached a plateau, but further improvements are expected with integration of targeted therapies. Epidermal growth factor receptor (EGFR)–directed therapies are of particular interest because the EGFR is frequently expressed in tumors and associated with poorer outcome. Thus, blockade of the EGFR should improve outcome. Blockade can be achieved by tyrosine kinase inhibitors (TKIs) or monoclonal antibodies (MoAbs). Both approaches have been evaluated in advanced NSCLC. As single agents, EGFR-directed TKIs have demonstrated efficacy in patients previously treated with chemotherapy. When combined with firstline platinum-based chemotherapy, TKIs failed to improve the outcome. In contrast, MoAbs in combination with platinum-based first-line chemotherapy showed promising efficacy in phase II trials. Two phase III trials with chemotherapy with or without cetuximab have been performed in patients with advanced NSCLC. Other EGFR-directed MoAbs and TKIs are in earlier stages of clinical development.

References (57)

  • M Cobo et al.

    Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in nonsmall-cell lung cancer

    J Clin Oncol

    (2007)
  • S Sun et al.

    New molecularly targeted therapies for lung cancer

    J Clin Invest

    (2007)
  • J Mendelsohn

    Targeting the epidermal growth factor receptor for cancer therapy

    J Clin Oncol

    (2002)
  • Z Fan et al.

    Anti tumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts

    Cancer Res

    (1993)
  • A-P Meert et al.

    The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

    Eur Respir J

    (2002)
  • M Fukuoka et al.

    Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer

    J Clin Oncol

    (2003)
  • MG Kris et al.

    Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

    JAMA

    (2003)
  • FA Shepherd et al.

    Erlotinib in previously treated non-small-cell lung cancer

    N Engl J Med

    (2005)
  • F Ciardiello et al.

    Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

    Clin Cancer Res

    (2000)
  • FM Sirotnak et al.

    Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

    Clin Cancer Res

    (2000)
  • B Higgins et al.

    Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

    Anticancer Drugs

    (2004)
  • G Giaccone et al.

    Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1

    J Clin Oncol

    (2004)
  • RS Herbst et al.

    Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 2

    J Clin Oncol

    (2004)
  • RS Herbst et al.

    TRIBUTE: a phase III trial of Erlotinib Hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer

    J Clin Oncol

    (2005)
  • U Gatzemeier et al.

    Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

    J Clin Oncol

    (2007)
  • J Baselga

    Combining the anti-EGFR agent gefitinib with chemotherapy in non–small-cell lung cancer: How do we go from INTACT to Impact?

    J Clin Oncol

    (2004)
  • TORCH: a study of Tarceva or chemotherapy for the treatment of advanced non small cell lung cancer. ClinicalTrials.gov...
  • T Li et al.

    Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non–small cell lung cancer cells

    Clin Cancer Res

    (2007)
  • Cited by (18)

    • Predictive markers in the adjuvant therapy of non-small cell lung cancer

      2011, Lung Cancer
      Citation Excerpt :

      Thus, KRAS mutations do not appear to predict benefit from adjuvant treatment with gefitinib. EGFR-TKIs such as gefitinib and erlotinib have demonstrated efficacy in patients with advanced NSCLC [67,68], particularly in those who harbor activating mutations in the EGFR TK domain of their tumors [69–71]. These mutations were first identified in 2004 and shown to confer sensitivity to EGFR TKIs.

    • Monoclonal antibodies against EGFR in non-small cell lung cancer

      2011, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      According to a meta-analysis based on five adjuvant chemotherapy trials, the survival gain achieved by cisplatin-based protocols is absolute 5% at 5 years [7]. Customized chemotherapy [8] and targeted therapies are current strategies to improve the outcome of systemic therapy in patients with NSCLC [9–14]. Targeted therapies focus on the inhibition of growth factor receptor systems, angiogenesis or both [9–14].

    • Novel drugs against non-small-cell lung cancer

      2014, Current Opinion in Oncology
    View all citing articles on Scopus

    This summary includes discussion of investigational and/or unlabeled uses of drugs, including the use of gefitinib/chemotherapy, erlotinib/chemotherapy, cetuximab, matuzumab, and panitumumab in non–small-cell lung cancer.

    Dr Pirker has served as a paid consultant, served on a Speaker's Bureau, or been on the Advisory Board of Roche and Amgen.

    Ms Minar has no relevant relationships to disclose.

    Dr Filipits has no relevant relationships to disclose.

    View full text